C-kit expression in human osteosarcoma and in vitro assays

C-kit expression in human osteosarcoma and in vitro assays

Author Miiji, Luciana Nakao Odashiro Autor UNIFESP Google Scholar
Petrilli, Antonio Sergio Autor UNIFESP Google Scholar
Di Cesare, Sebastian Google Scholar
Odashiro, Alexandre Nakao Autor UNIFESP Google Scholar
Burnier, Miguel Noel Nascente Autor UNIFESP Google Scholar
Toledo, Silvia Regina Caminada de Autor UNIFESP Google Scholar
Garcia, Reynaldo Jesus Google Scholar
Alves, Maria Teresa de Seixas Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
McGill Univ
Ctr Hosp Afillie Univ Quebec
Abstract Biologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase in the pathogenesis of tumours. Osteosarcoma is a high grade aggressive neoplasm with poor survival. Our aim was to investigate c-kit immunoexpression, its prognostic relevance for patients with osteosarcoma, and the effect of imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line. A retrospective immunohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with high-grade primary osteosarcoma of extremities treated at the Pediatric Oncology Institute (IOP, GRAAC) and archived in the Department of Pathology, Federal University of Sao Paulo. Only pre-chemotherapy specimens were analyzed. Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data suggested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further studies are necessary to confirm this indication.
Keywords Osteosarcoma
c-kit
immunohistochemistry
in vitro assays
prognosis
Language English
Date 2011-01-01
Published in International Journal Of Clinical And Experimental Pathology. Madison: E-century Publishing Corp, v. 4, n. 8, p. 775-781, 2011.
ISSN 1936-2625 (Sherpa/Romeo, impact factor)
Publisher E-century Publishing Corp
Extent 775-781
Origin http://www.ijcep.com/1109006A.html
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000298346300006
URI http://repositorio.unifesp.br/11600/44032

Show full item record




File

Name: WOS000298346300006.pdf
Size: 593.7Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account